Lexicon Pharmaceuticals Announces Presentation of Diabetic Peripheral Neuropathic Pain Patient Insights at PAINWeek 2025

Core Insights - Lexicon Pharmaceuticals presented data on the physical and psychological impact of diabetic peripheral neuropathic pain (DPNP) at PAINWeek 2025, highlighting the inadequacy of current pain relief treatments [1][2] Company Overview - Lexicon Pharmaceuticals is a biopharmaceutical company focused on pioneering medicines that transform patients' lives, utilizing its Genome5000™ program to study nearly 5,000 genes and identify over 100 therapeutic protein targets [5] Product Development - Pilavapadin, an investigational small molecule inhibitor of AAK1, is being developed for DPNP, showing promise in preclinical studies for pain reduction without affecting opiate pathways [3][4] - Pilavapadin has received Fast Track designation from the U.S. FDA for its development in DPNP [4] Clinical Insights - Diabetic neuropathy affects nearly half of all diabetes patients, with 25-30% suffering from DPNP, which significantly impacts their quality of life [2] - A patient survey aimed at informing the advanced clinical development of Pilavapadin will be presented at PAINWeek 2025 [7]